Positive Phase III Results For Relenza Follow-On Owned By Aussie Biotech Biota, Japanese Daiichi Sankyo

PERTH, Australia - Australian biotech Biota Holdings announced positive Phase III results of its Asian clinical trials for second-generation influenza treatment CS-8958, co-developed and co-owned with Daiichi Sankyo